Adaptive Biotechnologies Corporation
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-59.5M | $-159.5M | $-225.3M | $-200.2M | $-207.3M | $-146.2M | $-68.6M | $-46.4M |
| Depreciation & Amortization | $16.0M | $17.4M | $19.6M | $20.9M | — | — | — | — |
| Depreciation | $16.1M | $17.6M | $20.5M | $19.2M | $12.3M | $6.8M | $6.1M | $4.3M |
| Amortization | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M |
| Stock-Based Compensation | $51.5M | $53.6M | $62.9M | $55.5M | $43.3M | $24.8M | $13.1M | $11.1M |
| Net Cash from Operating Activities | $-46.0M | $-95.2M | $-156.3M | $-183.9M | $-192.7M | $-149.7M | $205.4M | $-32.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $3.0M | $3.7M | $10.7M | $16.3M | $61.7M | $18.8M | $11.2M | $6.3M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $38.0M | $77.8M | $129.6M | $2.9M | $181.2M | $-117.0M | $-481.7M | $736.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $30.4M | $241.0K | $2.2M | $132.3M | $27.1M | $293.6M | $319.9M | $1.2M |
| Net Change in Cash | $22.4M | $-17.2M | $-24.4M | $-48.8M | $15.6M | $26.9M | $43.6M | $-30.3M |
| Free Cash Flow | $-48.9M | $-98.9M | $-167.0M | $-200.3M | $-254.5M | $-168.5M | $194.2M | $-38.6M |